SCYNEXIS, Inc.
(NASDAQ : SCYX)

( )
SCYX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
4.81%16.122.0%$220.21m
SHPGShire PLC Sponsored ADR
-0.43%180.080.4%$214.20m
PRGOPerrigo Co. Plc
-2.94%63.476.8%$106.37m
JAZZJazz Pharmaceuticals Plc
-5.91%141.792.2%$102.24m
ENDPEndo International Plc
-4.51%12.918.9%$68.26m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-2.22%129.256.3%$64.77m
MNKMallinckrodt Plc
-0.52%30.9121.1%$56.81m
SAGESAGE Therapeutics, Inc.
-0.90%108.059.6%$54.08m
ICPTIntercept Pharmaceuticals, Inc.
-4.15%96.5318.7%$48.16m
HZNPHorizon Pharma plc
-2.79%21.247.4%$47.64m
UTHRUnited Therapeutics Corporation
-1.55%110.9714.4%$43.54m
CTLTCatalent Inc
-0.84%37.902.4%$38.09m
PTLAPortola Pharmaceuticals, Inc.
-4.48%19.187.7%$34.63m
ICLRICON Plc
-1.62%135.764.1%$33.24m
AERIAerie Pharmaceuticals, Inc.
-4.43%41.406.9%$28.35m

Company Profile

SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.